Our last two picks have been solid winners.
Our July 5th pick surged as high as $1.80 for a +267% gain over our original buy call of $0.4899 per share.
Last Monday's alert opened the session 'Gap-Free' and ran from $0.39 to $0.511 per share for as much as +31.03% in realistic same-day profit!
That's +298% in profit with our last two picks alone....
Now it's time to deliver big winner number 3!
Please turn your attention to CTXR (Citius Pharmaceuticals, Inc.).
CTXR has yet to really grab the market's attention, but we think that is going to change very soon.
CTXR currently has one product in Phase 3 of FDA approval, and another in Phase 2.
These are the last stages before FDA approval, which is important because in most cases a new drug approval can lead to a higher share price for the company on the receiving end of that approval.
The fact that CTXR has two products this close to FDA approval should have traders licking their chops to get in on the action.
CTXR is in the midst of bullish chart reversal that has caused shares to climb over +42% in just two weeks time!
CTXR closed Friday's session up over 8%, and just below its high-of-day price.
We are quite confident that this bullish momentum is going to carry over into Monday for some significant gains.
We are urging all of our members to act now and add CTXR to the top of their watchlists.
About the Company:
CTXR (Citius Pharmaceuticals, Inc.). is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. CTXRseeks to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, they seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. CTXR is focused on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches.
Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge.
Mino-Lok is intended to salvage the CVC obviating the need to remove and replace the catheter. This is a recognized unmet medical need. There are no alternatives other than the removal and reinsertion of the CVC once the CVC becomes infected. Studies show that removal and reinsertion of CVCs have a 15 to 20% complication rate, including pneumothorax, misplacement, and arterial puncture.
Mino-Lok contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. The Mino-Lok™ product is used in two-hour locking cycles allowing the CVC to be used for its intended purposes for the remaining 22 hours each day.
- Partnership with a leading cancer center and support from key industry opinion leaders.
- In a Phase 2b trial, the Mino-Lok demonstrated a 100% efficacy rate in salvaging infected CVCs; Mino-Lok had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced.
- FDA QIDP designation and patent protected until June 2024.
- Advancing to a Phase 3 pivotal superiority trial.
CTXR is developing a proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to persons suffering from Grade I and II hemorrhoids. Although there are numerous prescription and over-the-counter (OTC) products commonly used to treat hemorrhoids, none currently possess safety and efficacy data generated from rigorously conducted clinical trials. Citius believes its hydrocortisone-lidocaine product will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy in treating hemorrhoids, an uncomfortable and often recurring condition.
Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO
Chairman and CEO Leonard Mazur has purchased 5 million of its restricted shares from the Company for $3 million dollars. This substantial investment will enable the Company to continue its development efforts across its product portfolio, and to build the infrastructure necessary to support multiple product development efforts.
"I am extremely excited about the prospects of the Company, and believe that we have a strong portfolio in different, progressive stages of development," said Mr. Mazur. "Going forward, Citius will use the proceeds to assist operations and develop specialty pharmaceuticals that address unmet medical needs. In some cases, we will be the only drug product being developed in its respective area Citius now has the team and the assets in place to execute on our strategic business plan."
This March announcement really grabbed our attention because we love hearing when CEO's buy stock in company.
In our opinion this is a huge vote of confidence in the future of the company he controls and its stock price.
It appears that Mr. Mazur already has CTXR back on track, and we believe it will soon be reflected in its share price.
Professional market feedback suggests that there is an important need to develop an alternative to the standard of care for catheter-related blood stream infections (CRBSIs). Of the approximately 7 million central venous catheters (CVCs) used annually, about 500,000 or 7% become infected leading to serious, life threatening infections.
The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs.
Nearly 50% of adults will have experienced the pain, discomfort, itching, and bleeding associated with hemorrhoids at least once.
In the U.S. an estimated 10 million patients report symptoms of hemorrhoidal disease each year.
According to IMS, over 25 million units of topical combination prescription products for hemorrhoids were sold in the United States. during the twelve-month period ended June 2012, comprising an estimated $80 million annual market.
As we mentioned above, CTXR has been on an absolute tear in the month of July.
Shares of CTXR are now up +42.86% from there July 5th 52-week low of $0.70.
We believe that the company still has the potential to move much higher from our $1.00 buy call.
Traders have the opportunity to grab of shares of CTXR at a 60% discount from it's 52-week high of $2.50.
A run back to $2.50 from our alert price would net traders up to +150% in pure profit!
CTXR's chart is setting off short-term buy signals in 3 major technical indicators.
7 Day Average Directional Indicator: BUY
10 - 8 Day Moving Average Hilo Channel: BUY
20 Day Moving Average vs Price: BUY
We are confident that CTXR's bullish momentum is going to carry over into Monday for some significant gains.
We are urging all of our members to act now, and add it to the top of their watchlists.
To learn more about CTXR, please visit their website(s): www.citiuspharma.com
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)